Skip to main content
Erschienen in: Clinical Rheumatology 6/2008

01.06.2008 | Original Article

The evaluation of carotid intima-media thickness in children with familial Mediterranean fever

verfasst von: Harun Peru, Bülent Altun, Mustafa Doğan, Fatih Kara, Ahmet Midhat Elmaci, Bülent Oran

Erschienen in: Clinical Rheumatology | Ausgabe 6/2008

Einloggen, um Zugang zu erhalten

Abstract

The aim is to investigate whether pediatric familial Mediterranean fever (FMF) patients have an increased risk of premature atherosclerosis and to determine the possible strength of association between atherosclerosis and Mediterranean fever (MEFV) gene mutation gene type. Demographic characteristics and MEFV mutations were defined in 49 children diagnosed with FMF (26 female, 23 male; mean age, 10.71 ± 3.69 years). Twenty-six age-, sex-, and body-mass-index-matched healthy children constituted the control group. We evaluated the blood counts and acute-phase proteins during attack-free periods. Mean C-reactive protein (CRP), serum amyloid-A (SAA), homocysteine (Hcy), lipoprotein-a (Lp-a), and common carotid artery intima-media thickness (CCA-IMT) were 10.75 ± 15.29 vs 4.03 ± 1.20, 23.22 ± 41.94 vs 3.53 ± 1.04, 10.36 ± 3.36 vs 8.64 ± 3.15, 20.84 ± 23.89 vs 8.56 ± 7.48, and 0.038 ± 0.007 vs 0.032 ± 0.004, respectively, and significantly higher than the mean values of control group (p < 0.05). However, no correlation was found between CCA-IMT and CRP, SAA, Hcy, and Lp-a. Twenty-nine patients had M694V mutation, and 13 patients had other mutations. There was no correlation between CCA-IMT and MEFV mutation subgroups. In conclusion, because of the nature of the disease, FMF patients should be considered to have an increased risk of early vascular alteration and atherosclerosis. For this reason, CCA-IMT measurement can be recommended as a noninvasive and early diagnostic method.
Literatur
1.
Zurück zum Zitat Korkmaz C, Ozdoğan, H, Kasapcopur O et al (2002) Acute phase response in familial Mediterranean fever. Ann Rheum Dis 61(1):79–81PubMedCrossRef Korkmaz C, Ozdoğan, H, Kasapcopur O et al (2002) Acute phase response in familial Mediterranean fever. Ann Rheum Dis 61(1):79–81PubMedCrossRef
2.
Zurück zum Zitat Lachmann HJ, Sengul B, Yavuzsen TU et al (2006) Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford) 45(6):746–750CrossRef Lachmann HJ, Sengul B, Yavuzsen TU et al (2006) Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford) 45(6):746–750CrossRef
3.
Zurück zum Zitat Haznedaroglu S, Ozturk MA, Sancak B et al (2005) Serum interleukin 17 and interleukin 18 levels in familial Mediterranean fever. Clin Exp Rheumatol 23(4 Suppl 38):77–80 Haznedaroglu S, Ozturk MA, Sancak B et al (2005) Serum interleukin 17 and interleukin 18 levels in familial Mediterranean fever. Clin Exp Rheumatol 23(4 Suppl 38):77–80
4.
Zurück zum Zitat Tunca M, Kirkali G, Soytürk M et al (1999) Acute phase response and evaluation of familial Mediterranean fever. Lancet 353:1415PubMedCrossRef Tunca M, Kirkali G, Soytürk M et al (1999) Acute phase response and evaluation of familial Mediterranean fever. Lancet 353:1415PubMedCrossRef
5.
Zurück zum Zitat Knecht A, de Beer FC, Pras M (1985) Serum amyloid A protein in familial Mediterranean fever. Ann Intern Med 102:71–72PubMed Knecht A, de Beer FC, Pras M (1985) Serum amyloid A protein in familial Mediterranean fever. Ann Intern Med 102:71–72PubMed
6.
Zurück zum Zitat Gang N, Drenth JP, Langevitz P et al (1999) Activation of the cytokine network in familial Mediterranean fever. J Rheumatol 26(4):890–897PubMed Gang N, Drenth JP, Langevitz P et al (1999) Activation of the cytokine network in familial Mediterranean fever. J Rheumatol 26(4):890–897PubMed
7.
Zurück zum Zitat Ridker PM, Buring JE, Cook NR et al (2003) C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 107:391–397PubMedCrossRef Ridker PM, Buring JE, Cook NR et al (2003) C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 107:391–397PubMedCrossRef
8.
Zurück zum Zitat Danesh J, Whincup P, Walker M et al (2000) Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 321:199–204PubMedCrossRef Danesh J, Whincup P, Walker M et al (2000) Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 321:199–204PubMedCrossRef
9.
Zurück zum Zitat Schillinger M, Exner M, Mlekusch W et al (2005) Inflammation and carotid artery—risk for atherosclerosis study (ICARAS). Circulation 111(17):2203–2209PubMedCrossRef Schillinger M, Exner M, Mlekusch W et al (2005) Inflammation and carotid artery—risk for atherosclerosis study (ICARAS). Circulation 111(17):2203–2209PubMedCrossRef
10.
Zurück zum Zitat Yang RZ, Lee MJ, Hu H et al (2006) Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications. PLoS Med 3(6):287CrossRef Yang RZ, Lee MJ, Hu H et al (2006) Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications. PLoS Med 3(6):287CrossRef
11.
Zurück zum Zitat Simon A, Gariepy J, Chironi G et al (2002) Intima-media thickness: a new tool for diagnosis and treatment of cardiovascular risk. J Hypertens 20:159–169PubMedCrossRef Simon A, Gariepy J, Chironi G et al (2002) Intima-media thickness: a new tool for diagnosis and treatment of cardiovascular risk. J Hypertens 20:159–169PubMedCrossRef
12.
Zurück zum Zitat Redberg RF, Vogel RA, Criqui MH et al (2003) Task force #3—What is the spectrum of current and emerging techniques for the noninvasive measurement of atherosclerosis. J Am Coll Cardiol 41(11):1886–1898PubMedCrossRef Redberg RF, Vogel RA, Criqui MH et al (2003) Task force #3—What is the spectrum of current and emerging techniques for the noninvasive measurement of atherosclerosis. J Am Coll Cardiol 41(11):1886–1898PubMedCrossRef
13.
Zurück zum Zitat Lorenz MW, Markus HS, Bots ML et al (2007) Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 115(4):459–467PubMedCrossRef Lorenz MW, Markus HS, Bots ML et al (2007) Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 115(4):459–467PubMedCrossRef
14.
Zurück zum Zitat Sattar N, McCarey DW, Capell H et al (2003) Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108(24):2957–2963PubMedCrossRef Sattar N, McCarey DW, Capell H et al (2003) Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108(24):2957–2963PubMedCrossRef
15.
Zurück zum Zitat de Leeuw K, Freire B, Smit AJ et al (2006) Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus. Lupus 15(10):675–682PubMedCrossRef de Leeuw K, Freire B, Smit AJ et al (2006) Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus. Lupus 15(10):675–682PubMedCrossRef
16.
Zurück zum Zitat Atabek ME, Kurtoglu S, Pirgon O et al (2006) Arterial wall thickening and stiffening in children and adolescents with type 1 diabetes. Diabetes Res Clin Pract 74(1):33–40PubMedCrossRef Atabek ME, Kurtoglu S, Pirgon O et al (2006) Arterial wall thickening and stiffening in children and adolescents with type 1 diabetes. Diabetes Res Clin Pract 74(1):33–40PubMedCrossRef
17.
Zurück zum Zitat Livneh A, Langevitz P, Zemer D et al (1997) Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 40:1879–1885PubMedCrossRef Livneh A, Langevitz P, Zemer D et al (1997) Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 40:1879–1885PubMedCrossRef
18.
Zurück zum Zitat Rosner B, Prineas RJ, Loggie JM et al (1993) Blood pressure nomograms for children and adolescents, by height, sex, and age in the United States. J Pediatr 123:871–886PubMedCrossRef Rosner B, Prineas RJ, Loggie JM et al (1993) Blood pressure nomograms for children and adolescents, by height, sex, and age in the United States. J Pediatr 123:871–886PubMedCrossRef
19.
Zurück zum Zitat Coskun T (1999) Hiperlipoproteinemili hastaların uzun süreli izlemi. Katkı Pediatr Derg 20:506–535 Coskun T (1999) Hiperlipoproteinemili hastaların uzun süreli izlemi. Katkı Pediatr Derg 20:506–535
20.
Zurück zum Zitat Akar N, Misirlioglu M, Yalcinkaya F et al (2000) MEFV mutations in Turkish patients suffering from familial Mediterranean fever. Human Mutat 15:118–119CrossRef Akar N, Misirlioglu M, Yalcinkaya F et al (2000) MEFV mutations in Turkish patients suffering from familial Mediterranean fever. Human Mutat 15:118–119CrossRef
21.
Zurück zum Zitat Pignoli P, Tremoli E, Poli A et al (1986) Intimal plus medial thicness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 6:1399–1406 Pignoli P, Tremoli E, Poli A et al (1986) Intimal plus medial thicness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 6:1399–1406
22.
Zurück zum Zitat Ridker PM, Rifai N, Rose L et al (2002) Comparison of C-reactive protein and low-density protein cholesterol levels in the prediction of first cardiovascular events. N Eng J Med 347:1557–1565CrossRef Ridker PM, Rifai N, Rose L et al (2002) Comparison of C-reactive protein and low-density protein cholesterol levels in the prediction of first cardiovascular events. N Eng J Med 347:1557–1565CrossRef
23.
Zurück zum Zitat Duell PB, Malinow MR (1997) Homocyst(e)ine: an important risk factor for atherosclerotic vascular disease. Curr Opin Lipidol 8(1):28–34PubMedCrossRef Duell PB, Malinow MR (1997) Homocyst(e)ine: an important risk factor for atherosclerotic vascular disease. Curr Opin Lipidol 8(1):28–34PubMedCrossRef
24.
Zurück zum Zitat Stampfer MJ (1997) Homocysteine levels and cardiovascular disease. Am Fam Phys 56(6):1571–1572 Stampfer MJ (1997) Homocysteine levels and cardiovascular disease. Am Fam Phys 56(6):1571–1572
25.
Zurück zum Zitat Jacobs P, Wood L, Bick R (2006) Homocysteine in vascular disease: an emerging clinical perspective. Cardiovasc J South Afr 17(3):135–139 Jacobs P, Wood L, Bick R (2006) Homocysteine in vascular disease: an emerging clinical perspective. Cardiovasc J South Afr 17(3):135–139
26.
Zurück zum Zitat Wild SH, Fortmann SP, Marcovina SM (1997) A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants. Arterioscler Thromb Vasc Biol 17(2):239–245PubMed Wild SH, Fortmann SP, Marcovina SM (1997) A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants. Arterioscler Thromb Vasc Biol 17(2):239–245PubMed
27.
Zurück zum Zitat Sigurdsson G, Baldursdottir A, Sigvaldason H et al (1992) Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. Am J Cardiol 69:1251–1254PubMedCrossRef Sigurdsson G, Baldursdottir A, Sigvaldason H et al (1992) Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. Am J Cardiol 69:1251–1254PubMedCrossRef
28.
Zurück zum Zitat Schaefer EJ, Lamon-Fava S, Jenner JL et al (1994) Lipoprotein(a) levels and risk of coronary heart disease in men: the Lipid Research Clinics Coronary Primary Prevention Trial. JAMA 271:999–1003PubMedCrossRef Schaefer EJ, Lamon-Fava S, Jenner JL et al (1994) Lipoprotein(a) levels and risk of coronary heart disease in men: the Lipid Research Clinics Coronary Primary Prevention Trial. JAMA 271:999–1003PubMedCrossRef
29.
Zurück zum Zitat Lorenz MW, Von Kegler S, Steinmetz H et al (2006) Carotid intima-media thickening indicates a higher vascular risk across a wide age range: prospective data from the Carotid Atherosclerosis Progression Study (CAPS). Stroke 37(1):87–92PubMedCrossRef Lorenz MW, Von Kegler S, Steinmetz H et al (2006) Carotid intima-media thickening indicates a higher vascular risk across a wide age range: prospective data from the Carotid Atherosclerosis Progression Study (CAPS). Stroke 37(1):87–92PubMedCrossRef
30.
Zurück zum Zitat Wadwa RP (2006) Cardiovascular disease risk in youth with diabetes mellitus. Rev Endocr Metab Disord 7(3):197–204PubMedCrossRef Wadwa RP (2006) Cardiovascular disease risk in youth with diabetes mellitus. Rev Endocr Metab Disord 7(3):197–204PubMedCrossRef
31.
Zurück zum Zitat Akdogan A, Calguneri M, Yavuz B et al (2006) Are familial Mediterranean fever (FMF) patients at increased risk for atherosclerosis? Impaired endothelial function and increased intima media thickness are found in FMF. J Am Coll Cardiol 48(11):2351–2353PubMedCrossRef Akdogan A, Calguneri M, Yavuz B et al (2006) Are familial Mediterranean fever (FMF) patients at increased risk for atherosclerosis? Impaired endothelial function and increased intima media thickness are found in FMF. J Am Coll Cardiol 48(11):2351–2353PubMedCrossRef
32.
Zurück zum Zitat Sari I, Karaoglu O, Can G et al (2007) Early ultrasonographic markers of atherosclerosis in patients with familial Mediterranean fever. Clin Rheumatol 26(9):1467–1473PubMedCrossRef Sari I, Karaoglu O, Can G et al (2007) Early ultrasonographic markers of atherosclerosis in patients with familial Mediterranean fever. Clin Rheumatol 26(9):1467–1473PubMedCrossRef
33.
Zurück zum Zitat Schwabe AD, Peters RS (1974) Familial Mediterranean Fever in Armenians. Analysis of 100 cases. Medicine (Baltimore) 53:453–462CrossRef Schwabe AD, Peters RS (1974) Familial Mediterranean Fever in Armenians. Analysis of 100 cases. Medicine (Baltimore) 53:453–462CrossRef
34.
Zurück zum Zitat Langevitz P, Livneh A, Neumann L et al (2001) Prevalance of ischemic heart disease in patients with familial Mediterranean fever. Isr Med Assoc J 3:9–12PubMed Langevitz P, Livneh A, Neumann L et al (2001) Prevalance of ischemic heart disease in patients with familial Mediterranean fever. Isr Med Assoc J 3:9–12PubMed
35.
Zurück zum Zitat Dewalle M, Domingo C, Rozenbaum M et al (1998) Phenotype–genotype correlation in Jewish patients suffering from familial Mediterranean fever. Eur J Hum Genet 6:95–97PubMedCrossRef Dewalle M, Domingo C, Rozenbaum M et al (1998) Phenotype–genotype correlation in Jewish patients suffering from familial Mediterranean fever. Eur J Hum Genet 6:95–97PubMedCrossRef
36.
Zurück zum Zitat Shohat M, Magal N, Shohat T (1999) Phenotype–genotype correlation in familial Mediterranean fever: evidence for an association between Met694Val and amyloïdosis. Eur J Hum Genet 7:287–292PubMedCrossRef Shohat M, Magal N, Shohat T (1999) Phenotype–genotype correlation in familial Mediterranean fever: evidence for an association between Met694Val and amyloïdosis. Eur J Hum Genet 7:287–292PubMedCrossRef
37.
Zurück zum Zitat Kone Paut I, Dubuc M, Sportouch J et al (2000) Phenotype-genotype correlation in 91 patients with familial Mediterranean fever reveals a high frequency of cutaneomucous features. Rheumatology (Oxford) 39(11):1275–1279CrossRef Kone Paut I, Dubuc M, Sportouch J et al (2000) Phenotype-genotype correlation in 91 patients with familial Mediterranean fever reveals a high frequency of cutaneomucous features. Rheumatology (Oxford) 39(11):1275–1279CrossRef
38.
Zurück zum Zitat Tunca M, Akar S, Onen F et al (2005) Turkish FMF Study Group. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore) 84(1):1–11CrossRef Tunca M, Akar S, Onen F et al (2005) Turkish FMF Study Group. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore) 84(1):1–11CrossRef
39.
Zurück zum Zitat Sohar E, Gafni J, Pras M et al (1967) Familial Mediterranean fever: a survey of 470 cases and review of the literature. Am J Med 43:227–253PubMedCrossRef Sohar E, Gafni J, Pras M et al (1967) Familial Mediterranean fever: a survey of 470 cases and review of the literature. Am J Med 43:227–253PubMedCrossRef
Metadaten
Titel
The evaluation of carotid intima-media thickness in children with familial Mediterranean fever
verfasst von
Harun Peru
Bülent Altun
Mustafa Doğan
Fatih Kara
Ahmet Midhat Elmaci
Bülent Oran
Publikationsdatum
01.06.2008
Verlag
Springer-Verlag
Erschienen in
Clinical Rheumatology / Ausgabe 6/2008
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-007-0764-1

Weitere Artikel der Ausgabe 6/2008

Clinical Rheumatology 6/2008 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.